Stay informed about HealthSpan Research's latest developments, partnerships, and progress in advancing treatments for Alzheimer's disease.
MARLBOROUGH, MA – October 5, 2025 – HealthSpan Research LLC, a pioneering biotechnology company focused on developing innovative treatments for Alzheimer's disease, today announced it has been accepted as a member of the Alzheimer's Association Business Consortium (AABC).
The Alzheimer's Association Business Consortium brings together leading pharmaceutical, biotechnology, and diagnostic companies to accelerate the development of new treatments and diagnostic tools for Alzheimer's disease and other dementias. The consortium facilitates collaboration, knowledge sharing, and pre-competitive research initiatives among its members.
"We are deeply honored to be accepted into the Alzheimer's Association Business Consortium. This membership represents an important milestone for our company and validates our innovative approach to treating Alzheimer's disease. We look forward to working closely with consortium members and the Alzheimer's Association to advance new treatments for the millions of people afflicted with this devastating disease."
– Brian Packard, Co-founder and CEO, HealthSpan Research
HealthSpan Research is developing a revolutionary approach to treating Alzheimer's disease through exosome-based therapeutics. The company's research focuses on harnessing the natural biological properties of exosomes to deliver therapeutic interventions across the blood-brain barrier.
More than 6 million Americans currently live with Alzheimer's disease, and that number is projected to grow to nearly 13 million by 2050. The disease is the sixth-leading cause of death in the United States and the fifth-leading cause of death among those age 65 and older.
HealthSpan Research is a biotechnology company dedicated to pioneering revolutionary approaches to treating Alzheimer's disease. Based in Marlborough, Massachusetts, the company focuses on developing exosome-based therapeutics designed to address the underlying mechanisms of neurodegenerative disease. For more information, visit www.h-spanresearch.com.
HealthSpan Research LLC
617.620.0759
info@h-spanresearch.com